Harnessing nanoencapsulation for the repurposing of hydroquinidine against breast cancer
Lade...
Autor:in (Körperschaft)
Publikationsdatum
08.2025
Typ der Arbeit
Studiengang
Typ
01A - Beitrag in wissenschaftlicher Zeitschrift
Herausgeber:innen
Herausgeber:in (Körperschaft)
Betreuer:in
Übergeordnetes Werk
Journal of Drug Delivery Science and Technology
Themenheft
DOI der Originalpublikation
Link
Reihe / Serie
Reihennummer
Jahrgang / Band
110
Ausgabe / Nummer
Seiten / Dauer
107098
Patentnummer
Verlag / Herausgebende Institution
Elsevier
Verlagsort / Veranstaltungsort
Auflage
Version
Programmiersprache
Abtretungsempfänger:in
Praxispartner:in/Auftraggeber:in
Zusammenfassung
Repurposing drugs beyond their original medical indications can facilitate cost- and time-effective drug development and a sustainable drug development process. Nanoencapsulation strategies can further expand the number of potentially suitable drug candidates for repurposing. In this study, we explored the anticancer efficacy of hydroquinidine (a class IA antiarrhythmic cinchona alkaloid drug) loaded into PLGA nanoparticles (HQ-NP) on breast cancer cells. The study compared HQ-NP to soluble hydroquinidine (HQsol) in estrogen receptor-positive MCF7 and triple-negative MDA-MB-231 breast cancer cell lines. Overall, nanoencapsulation resulted in more potent and selective toxicity in comparison to soluble drug. The mechanisms involved inducing apoptosis and oxidative stress, disruption of mitochondrial membrane potential, and suppression of cell proliferation. The enhanced potency of HQ-NP was consistent across multiple assays and on both cell lines, suggesting a broad applicability in different breast cancer subtypes. In silico analyses indicated the cancer-related pathways, such as PI3K-Akt and cAMP signaling, as potential targets of HQ, which is likely to be driven by the putative inhibition of voltage-gated ion channels as suggested by molecular docking studies. This research highlights the potential of HQ-NP as a novel, multi-modal anticancer agent for breast cancer treatment, warranting further investigation towards clinical application.
Schlagwörter
Anticancer efficacy, Breast cancer, Drug delivery, Hydroquinidine, Nanoencapsulation, PLGA nanoparticles
Fachgebiet (DDC)
Veranstaltung
Startdatum der Ausstellung
Enddatum der Ausstellung
Startdatum der Konferenz
Enddatum der Konferenz
Datum der letzten Prüfung
ISBN
ISSN
1773-2247
2588-8943
2588-8943
Sprache
Englisch
Während FHNW Zugehörigkeit erstellt
Ja
Zukunftsfelder FHNW
Future Health
Publikationsstatus
Veröffentlicht
Begutachtung
Peer-Review der ganzen Publikation
Open Access-Status
Hybrid
Lizenz
Zitation
Demircan, T., Milinkovic, D., Çetin, E. S., Aksu, E., & Tagit, O. (2025). Harnessing nanoencapsulation for the repurposing of hydroquinidine against breast cancer. Journal of Drug Delivery Science and Technology, 110, 107098. https://doi.org/10.1016/j.jddst.2025.107098